[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine].
BACKGROUND
Ibopamine is a non-selective dopamine- and adrenalin-receptor agonist that has been shown to cause pupillary dilation and an increase in aqueous humour secretion. This novel drug can be used as a mydriatic agent, as a provocative test in open-angle glaucoma, and for the treatment of persisting ocular hypotony.


METHODS
This 47-year-old man had a history of uveitis associated with Crohn's disease. Six years after deep sclerectomy for uveitic secondary glaucoma, he developed severe hypotony in his left eye with drop of visual acuity (VA). The hypotony did not respond to topical steroid treatment. 2 % Ibopamine solution was ordered t. i. d. concomitant to 1 % prednisolone acetate.


RESULTS
Intraocular pressure (IOP) began to rise after 3 weeks of Ibopamine treatment and returned to normal (12 mmHg) with continuous recovery of VA after 8 weeks. Ibopamine was discontinued at an IOP of 16 mmHg after a course of 12 weeks. IOP and VA remained stable during the 12-month follow-up period.


CONCLUSIONS
Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony.
Windisch
B K
BK
Universitäts-Augenklinik, Inselspital Bern, Schweiz. bettina.windisch@insel.ch
Iliev
M E
ME
D000287:Administration, Topical; D002908:Chronic Disease; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage; D015814:Ocular Hypotension / Q000209:etiology* / Q000517:prevention & control*; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications* / Q000188:drug therapy*
D009184:Mydriatics; C023487:ibopamine; D003846:Deoxyepinephrine